Article

Development and refinement of a technique using a medical radiation therapy facility to irradiate immunodeficient mice bearing xenografted human tumours.

Translational Research Laboratory, Catalan Institute of Oncology and IDIBELL, Avinguda Gran Via de l'Hospitalet, 199-203, 08907 l'Hospitalet de Llobregat, Spain.
Laboratory Animals (Impact Factor: 1.26). 06/2012; 46(4):345-8. DOI: 10.1258/la.2012.011147
Source: PubMed

ABSTRACT The need for using immunodeficient mice for xenoimplantation of tumours is increasing in translational research in radiation oncology. However, adverse effects of radiation and infectious diseases may ruin the experimental work, in particular when appropriate facilities are not available. In this report, we describe a procedure to deliver fractionated radiotherapy to xenoimplanted tumours in immunodeficient mice using a medical linear accelerator, a method that was devised as an alternative to the lack of facilities devoted to radiation research. The mice were irradiated under anaesthesia and aseptic conditions. Thirty Gray in 10 days using a 6 MV photon beam were delivered only to the right thigh of the mice where tumours were implanted. The mice were evaluated twice a week up to planned euthanasia. The follow-up of mice was completed without premature interruption due to toxicities or infectious diseases, an observation which demonstrates the feasibility of the method.

0 Bookmarks
 · 
47 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Radiotherapy delivered with the antibody cetuximab is a standard treatment option for locally advanced head and neck cancer. Cetuximab acts by blocking epidermal growth factor receptor (EGFR) signaling to inhibit cancer progression. However, a significant percentage of patients will not respond satisfactorily to radiotherapy and cetuximab. Statins reduce the synthesis rate of cholesterol and isoprenoid derivates that may be required for an efficient cell signaling mediated by EGFR. We pre-clinically assessed whether the statin simvastatin could improve this combined therapy. In vitro, simvastatin enhanced the effects of radiotherapy alone and in combination with cetuximab in wound healing, cell proliferation, and clonogenic assays in FaDu cells. These results were reflected in xenoimplanted tumors growing into subcutaneous tissue of athymic mice where concomitant treatment with simvastatin decreased tumor growth. Consistently, lower levels of the phosphorylated ERK1/2, AKT and STAT3 oncoproteins, and higher levels of caspase-3 and apoptosis in cell cultures and xenografts were observed. The EGFR overexpressing A431 cell line was used to reproduce these antitumor effects of simvastatin. Our findings suggest that simvastatin may improve the efficiency of concomitant radiotherapy and cetuximab. Further investigation in the treatment of locally advanced tumors such as head and neck cancer is warranted.
    Translational oncology 01/2014; · 3.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Radiation resistance is a major cause of death in cancer patients. Cancer cells react during radiotherapy by re-programming specific cell functions that may confer resistance to radiation. The understanding of this complex process is hindered due to the lack of appropriate study models. We describe an experimental development of a radioresistant isogenic cancer cell line, and its molecular characterization. MATERIALS AND METHODS: A431-cultured cells were irradiated for 7 month until 85 Gy. Then, a selected single cell was left to grow as stable A431-R cell line. Clonogenic assay was used to determine cell survival, the α and β parameters of the LQ model, and the mean inactivation dose. The DNA repair ability of cells was evaluated by pulsed-field electrophoresis method. Differential effect of fractionated radiation was ultimately tested in xenografts. Furthermore, we used a wound healing assay, Western blot for EGFR, AKT and ERK1/2 and ELISA test for vascular endothelial growth factor (VEGF) secretion. Finally we explored CD44 marker and cell cycle distribution. RESULTS: The established A431-R cell line showed radiation resistance in clonogenic assays, repair of radiation-induced DNA fragmentation and xenografted tumours. The radiation resistance was associated with in vitro higher cell growth and migration, increased levels of former oncoproteins, and secretion of VEGF. CONCLUSIONS: In this model, the emergence of radiation resistance was associated with the acquisition of biological traits that support more aggressive behaviour of cancer cells. We have generated a model that will be useful for mechanistic studies and development of rational treatments against radiation resistance in cancer.
    Clinical and Translational Oncology 07/2012; · 1.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Für die translationale Krebsforschung sind präklinische in-vivo-Untersuchungen an Kleintieren unverzichtbar, um Erkenntnisse aus in-vitro-Zellexperimenten vor der klinischen Einführung zu validieren. Bei der Konzeption solcher Tierexperimente müssen verschiedene biologische, technische und methodische Aspekte betrachtet werden. Dieser Übersichtsartikel gibt eine umfangreiche Zusammenfassung zur Bestrahlung von Kleintieren wie Mäusen und Ratten basierend auf relevanten Publikationen dieses Forschungsgebietes. Klinische Bestrahlungsgeräte für Teletherapie und Brachtytherapie sowie dedizierte Bestrahlungsgeräte für die Forschung sind zur Bestrahlung von Kleintieren geeignet. Dies hängt jedoch wesentlich vom Tiermodell und den Forschungszielen ab. Geeignete Lösungen werden vorgestellt, welche die verfügbaren Technologien der humanen Strahlentherapie auf die präklinische Forschung mit Kleintieren übertragen. Des Weiteren werden wichtige Entscheidungshilfen für die Experimentplanung zusammengefasst, die zur Erzielung zuverlässiger, klinisch relevanter Ergebnisse zu beachten sind.
    Zeitschrift für Medizinische Physik 08/2014; · 1.21 Impact Factor

Full-text

View
2 Downloads
Available from
Aug 5, 2014